Patents by Inventor Tanya Amanda CAMACHO VILLEGAS

Tanya Amanda CAMACHO VILLEGAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF
    Patent number: 10370442
    Abstract: The present invention refers to the selection, isolation and purification of proteins belonging to variable regions named VHNAR or vNAR, originated from IgNAR-type immunoglobulins of elasmobranches with antigen receptor abilities. The clones from which they originate are named VEGFvNAR V32R and V19; and the antibodies are named V32R and V19. Their amino acid sequences and tertiary structures were elucidated, and their ability to neutralize the vascular endothelial growth factor (VEGF) activity was determined. During the development of the invention these proteins were optimized for expression in a production model of E. coli at industrial level. The invention involves the use of these antibodies in general to treat conditions related to angiogenesis or neovascularization and in particular to treat neovascularization-related ophthalmic conditions by topical administration.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: August 6, 2019
    Assignee: TERACLON IDF, S.L.
    Inventors: Carolina Elosua Portugal, Maria Teresa Mata Gonzalez, Tanya Amanda Camacho Villegas, Araceli Olguin Jimenez, Alexei Fedorovish Licea Navarro, Jorge Fernando Paniagua Solis
  • VNAR RECOMBINANT MONOCLONAL ANTIBODIES THAT NEUTRALIZE VASCULAR ENDOPHELIAL GROWTH FACTOR VEGF
    Publication number: 20170137504
    Abstract: The present invention refers to the selection, isolation and purification of proteins belonging to variable regions named VHNAR or vNAR, originated from IgNAR-type immunoglobulins of elasmobranches with antigen receptor abilities. The clones from which they originate are named VEGFvNAR V32R and V19; and the antibodies are named V32R and V19. Their amino acid sequences and tertiary structures were elucidated, and their ability to neutralize the vascular endothelial growth factor (VEGF) activity was determined. During the development of the invention these proteins were optimized for expression in a production model of E. coli at industrial level. The invention involves the use of these antibodies in general to treat conditions related to angiogenesis or neovascularization and in particular to treat neovascularization-related ophthalmic conditions by topical administration.
    Type: Application
    Filed: April 17, 2014
    Publication date: May 18, 2017
    Inventors: Carolina ELOSUA PORTUGAL, María Teresa MATA GONZÁLEZ, Tanya Amanda CAMACHO VILLEGAS, Araceli OLGUÍN JIMÉNEZ, Alexei Fedorovish LICEA NAVARRO, Jorge Fernando PANIAGUA-SOLÍS